RTOG-0521
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
Principal Investigator
Howard M. Sandler
Status
Terminated
Closed to Accrual & Treatment
June 16, 2010
Complete
April 15, 2014
Complete
March 12, 2019
Terminated
May 20, 2022
Disease Site
Genitourinary [GU] Prostate
Phase
III
Developmental Therapeutics
No
Patient Population
–
Target Accrual
600
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
